Considerable effort has been invested in searching for less invasive methods of diagnosing endometriosis. Previous studies have indicated altered levels of the CALD1 gene (encoding the protein caldesmon) in endometriosis. The aims of our study were to investigate whether average CALD1 expression and caldesmon protein levels are differentially altered in the endometrium and endometriotic lesions and to evaluate the performance of the CALD1 gene and caldesmon protein as potential biomarkers for endometriosis. Paired biopsies of endometrial tissue (eutopic endometrium) and endometriotic lesions (ectopic endometrium) were obtained from patients with endometriosis to evaluate CALD1 gene expression and caldesmon protein levels by real-time PCR and Western blot analysis, respectively. In addition, immunostaining for caldesmon to determine cellular localization was also performed. Endometrium from women without endometriosis was used as a control. Increased CALD1 expression and caldesmon levels were detected in the endometriotic lesions. The electrophoretic profile of caldesmon by Western blot analysis was clearly different between the control group (endometrium of women without endometriosis) and the group of women with endometriosis (eutopic endometrium and endometriotic lesions). Caldesmon expression as determined by immunostaining showed no variation among the cell types in endometriotic lesions and eutopic endometrium. Stromal cells marked positively in eutopic endometrium from control patients and in the endometriotic lesions. The presence of caldesmon in the endometrium of patients with and without endometriosis permitted diagnoses with 95% sensitivity (specificity 100%) and 100% sensitivity (specificity 100%) for the disease and for minimal to mild endometriosis in the proliferative phase of the menstrual cycle, respectively. In the secretory phase, minimal to mild endometriosis was detected with 90% sensitivity and 93.3% specificity. Caldesmon is a possible predictor of endometrial dysregulation in patients with endometriosis. A potential limitation of our study is the fact that other endometrial diseases were not excluded, and therefore prospective studies are needed to confirm the potential of caldesmon as a biomarker exclusively for endometriosis.
INTRODUCTION
Endometriosis is a common benign gynecological disease that affects at least 10% of women of reproductive age [1] . This condition is characterized by the growth of glands and endometrial stroma outside the uterine cavity, which are known as ectopic tissues [2] . These lesions may be associated with infertility and pain symptoms, including cyclic pelvic pain, dysmenorrhea, dyspareunia, dysuria, and dyschezia. There is a low correlation between the type of lesion and the symptoms of the disease [3] .
The gold standard for diagnosing endometriosis is direct inspection of the abdominal cavity by laparoscopy [4] plus histological confirmation of ectopic endometrial tissue [5] . However, this procedure is costly; moreover, the diagnostic accuracy of the method is affected by the level of experience of the surgeon [6] . This heterogeneity in clinical presentation and the need for an invasive procedure for diagnostic confirmation justify the search for a sensitive marker of low invasiveness [7] .
Considerable effort has been invested in searching for noninvasive methods for diagnosing endometriosis and in understanding the physiopathology of the disease [8] . Many reports have suggested that various serum, peripheral blood, peritoneal fluid, urine, endometrial fluid, and biopsy markers are associated with endometriosis, such as tumor markers and polypeptides (CA-125, CA 19-9, SICAM-1), immunological markers (IL-6, TNF, antiendometrial antibodies and autoantibodies, and markers of oxidative stress), genetic markers (EGR-1, P450 aromatase, and PP14), circulating cell-free DNA, and tissue markers (P450 aromatase, cytokeratins, hormone receptors, PGP9.5-immunoactive nerve fibers) [7, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The most commonly used serum marker for the clinical diagnosis of endometriosis, CA-125, is inadequate for the routine clinical assessment of endometriosis [20] because it has limited diagnostic accuracy in identifying early-stage endometriosis [21] .
The expression of the CALD1 gene determined by screening has been reported to be increased in patients with endometriosis [22] [23] [24] [25] . The human CALD1 gene encodes caldesmon, a protein found in the cytoskeleton [26] . Cytoskeletal proteins have been shown to play an important role in many cellular functions, such as proliferation, apoptosis, cell motility, adhesion, receptor function, and second messenger pathways. Several studies have shown that genes and proteins of the cytoskeleton, such as transgelin, moesin, and caldesmon, among others, are related to endometriosis [10, 12, 19, 22, 24, 27] . The objectives of the present study were to investigate whether average CALD1 expression and caldesmon protein levels are altered in the endometrium and in endometriotic lesions and to evaluate the performance of the CALD1 gene and caldesmon protein as potential biomarkers for endometriosis.
MATERIALS AND METHODS
This was not a blind study. The study was approved by the Research Ethics Committees of the Faculdade de Medicina de Ribeirão Preto. The participants were recruited at the tertiary hospital of the School of Medicine of Ribeirão Preto (University of São Paulo), and all of the participants gave informed written consent.
Patients and Samples
A case-control study was conducted on women with and without endometriosis in the proliferative and secretory phases of the menstrual cycle. Forty patients with a laparoscopic and histological diagnosis of endometriosis were selected. The subjects were 18 to 40 years old (mean, 33.5 6 0.72 yr), were not menopausal, had not been taking any hormone therapy for at least 6 mo before sample collection, and had no other reproductive disorders or any tumors. The indication for laparoscopy was infertility in 21 patients and pelvic pain in 19. The stage of endometriosis was determined according to the classification of the American Society for Reproductive Medicine [28] . Paired samples of eutopic endometrium and endometriotic lesions were obtained from 40 women. Only one lesion was collected per patient. Twenty peritoneal lesions were studied in patients staged as grade I (n ¼ 6, secretory phase), grade II (n ¼ 11, 7 proliferative and 4 secretory phase), grade III (n ¼ 2, proliferative phase), and grade IV (n ¼ 1, proliferative phase), and 20 lesions of ovarian endometrioma were studied in patients staged as grade III (n ¼ 8, 4 proliferative and 4 secretory phase) and grade IV (n ¼ 12, 6 proliferative and 6 secretory phase). Eutopic endometrium (n ¼ 40) was collected with a Novak curette during laparoscopy.
The control group consisted of 15 women of reproductive age without endometriosis, fibrosis, pelvic adhesions, or infertility, aged 18 to 40 years old (mean, 33.87 6 0.69 yr). These women were subjected to laparoscopy for tube ligation, with laparoscopic confirmation of the absence of endometriotic lesions and had not been taking hormone medication for at least 6 mo before biopsy collection. Two paired endometrial biopsies (control endometrium) were collected from these patients according to the phase of the menstrual cycle. Fifteen biopsies were obtained during the proliferative phase and 15 during the secretory phase of the menstrual cycle, as confirmed by histological dating. The biopsies were collected with a Novak curette, the first during the surgical procedure (during the proliferative phase of the menstrual cycle) and the second scheduled and obtained during the secretory phase of the same menstrual cycle.
The samples were stored in a freezer at À808C in a cryotube containing RNAlater Solution (Ambion Life Technologies) for RNA and protein preservation. In addition, part of the fresh tissues were fixed in neutral 4% formalin and embedded in paraffin for tissue structure preservation.
Gene Expression of CALD1
The samples were washed in 13 PBS (8.50 g/L NaCl, 1.11 g/L Na 2 HPO 4 , 2.81 g/L Na 2 HPO 4 . 12H 2 O, 0.20 g/L KH 2 PO 4 , pH 7.0) to remove the RNAlater Solution. Next, total RNA (50 mg tissue) was extracted with TRIzol reagent (Invitrogen Life Technologies) and treated with DNase I (Invitrogen Life Technologies) according to the manufacturer's instructions. The interphase and the phenol/chloroform organic phase were stored in a freezer at À808C for the isolation of total protein from the same samples. The RNA integrity was confirmed by the presence of 28S and 18S ribosome bands when analyzed by 1% agarose gel electrophoresis with 13 3-(N-morpholino) propane sulfonic acid buffer. Total RNA concentration was determined by spectrophotometry (NanoDrop 2000c; Thermo Scientific) at 260 nm. The extracted total RNA was stored in a freezer at À808C for subsequent use. One microgram of total RNA from each sample was reverse transcribed using the High Capacity cDNA Transcription Kit (Applied Biosystems Life Technologies) according to the manufacturer's instructions.
Relative quantification of the CALD1 gene in the 110 tissue samples that were collected were analyzed using an ABI PRISM 7500 FAST instrument (Applied Biosystems Life Technologies). The reactions were conducted using the TaqMan Gene Expression Assays (TaqMan minor groove binder probes, 6-carboxyfluorescein dye labeled) by Applied Biosystems Life Technologies. The assays were probed for CALD1 (Hs00189021_m1), GAPDH (Hs99999905_m1), and ACTB (Hs99999903_m1). Quantitative real-time PCR was performed in triplicate in a final volume of 20 ll using the following conditions: 10 ll TaqMan Universal PCR Master Mix (23) (Applied Biosystems Life Technologies), 1 ll TaqMan Gene Expression Assay (203) (Applied Biosystems Life Technologies), and 9 ll of cDNA diluted 1:50. The reaction conditions were as follows: 508C for 2 min, 958C for 10 min, and 40 cycles of 958C for 15 sec and 608C for 1 min.
The relative quantification of the CALD1 gene was calculated for each sample according to the 2-delta delta Ct (2 ÀDDCT ) method. A pool of cDNA containing equal quantities of endometrium samples obtained from women without endometriosis (control group) was used to calibrate the reactions. The GAPDH and ACTB genes were used as reference genes to normalize the reactions.
Western Blot Analysis
Total protein was extracted from the interphase and from the phenol/ chloroform organic phase obtained after total RNA isolation according to the TRIzol reagent protocol (Invitrogen Life Technologies). The pellet was diluted with 1% SDS, and protease and phosphatase inhibitors were added (SigmaAldrich). The protein concentration was determined in duplicate by the bicinchoninic assay method (Pierce). The proteins were denatured by boiling in 13 Laemmli sample buffer. Next, 10 lg of total protein per well was separated on a 1-mm thick 10% SDS-PAGE polyacrylamide gel (25 V for 16 h) and electroblotted onto (0.45-lm pore size) nitrocellulose membranes (Hybond; GE Healthcare) using the Mini Trans-Blot Electrophoretic Transfer Cell tank method (Bio-Rad) (350 mA, 90 min, cold). The efficiency of the transfer to the nitrocellulose membranes was verified by a brief staining of the blots with Ponceau red stain. These membranes were then blocked with Tris-buffered saline (TBS) containing 5% bovine serum albumin and 0.1% Tween-20 for 1 h at 48C. Next, the membranes were incubated for 16 h at 48C with an anticaldesmon antibody [12B5] (mouse monoclonal ab8247, 0.5 lg/ml dilution; Abcam) and monoclonal anti-b-actin (clone AC-15, A5441, 0.1 lg/ml dilution; Sigma-Aldrich). After washing with TBS containing 0.1% Tween-20, all of the membranes were incubated for 1 h at 48C with a rabbit polyclonal secondary antibody to mouse immunoglobulin G conjugated to horseradish peroxidase (ab6728, 1 lg/ml dilution; Abcam). The specific immunoreactive bands were detected by chemiluminescence (ECL Plus Western Blotting Detection System; GE Healthcare). Images were acquired with the Molecular Image Chemidoc XRS Imaging System (Bio-Rad) and quantified using Image Lab 3.0 (BioRad). The caldesmon levels were normalized to a b-actin reference control. To avoid bias in the quantification, comparisons were made before and after stripping on the membrane. Thus, the membrane was cut below the 55-kDa position of the molecular marker to hybridize the primary antibodies separately.
Immunohistochemistry
Fresh tissue had been routinely fixed in 4% neutral formalin and embedded in paraffin. Immunohistochemical staining was developed using the Novolink Max Polymer Detection System (Novocastra). Briefly, 3-lm thick sections were cut from paraffin blocks containing representative samples. Paraffin sections were dewaxed in xylene, rehydrated through a graded alcohol series, placed in 10 mM citrate buffer, and submitted to heat retrieval using a vapor lock for 40 min. After heating, the slides were allowed to cool to room temperature and briefly washed with TBS. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol for 30 min, followed by a single wash in ethylenediaminetetraacetic acid, pH 8.5. Normal serum (Novostain super-ABC kit; Novocastra) was used for 30 min in order to block any nonspecific immunoassay. The primary antibody (caldesmon E 89, 1:40 dilution; Cell Marque) was incubated overnight at 48C. The slides were then incubated with the postprimary solution for 30 min and incubated with the polymer for 30 min (both provided by Novolink Max Polymer Detection System). The reaction was stained with diaminobenzidine followed by hematoxylin counterstaining. The slides were then dehydrated in an ethanol series and mounted with Permount (Fischer). Myoma cases were used as the positive control for caldesmon. Negative control for immunostaining was prepared by omission of the primary antibody.
Statistical Analysis
The data are represented in figures on the original scale (box-and-whisker and dots). However, the variables of gene expression and protein levels were log 10 transformed. The logarithmic transformation was necessary because one of the assumptions (i.e., linearity) in the linear model analysis was not satisfied. These analyses specify that the conditional average E (yx ¼ x 0 ) from the response variable y (CALD1 measures), given the x 0 value of the predictor vector x (independent variable; endometriosis), is linear in x 0 .The application of the linear models can be extended assuming that an appropriate
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(the nonlinear coefficient that estimates the effects of the endometriosis in CALD1 measures). The term e (random error) is independent of x and has an average of zero [29] . The analyses were performed using the SAS 2003 software (SAS Institute Inc.). The analysis of variance that was performed in the statistical model included the effects of phases of menstrual cycle (proliferative and secretory), the type of tissue (ovary and peritoneum lesions and eutopic and control endometrium), as well as the interactions among them. A t-test for paired samples (eutopic endometrium versus ectopic lesions) and Welch ANOVA for unpaired samples (control endometrium versus eutopic endometrium of patients with endometriosis; control endometrium versus lesions of patients with endometriosis; peritoneal lesions versus ovarian lesions) were used to compare the means of the data obtained
The diagnostic performance of CALD1 expression and caldesmon protein levels were assessed using receiver operating characteristic (ROC) curves (MedCalc statistical software) [30] to plot the test sensitivity versus the falsepositive rate and to determine the usefulness of a diagnostic test over a range of possible clinical results; 95% confidence intervals were obtained for the various ROC curves. The data used in this analysis were obtained from the endometrium of women with and without endometriosis during both the proliferative and the secretory phases of the menstrual cycle.
RESULTS
Comparisons between peritoneal lesions and endometriomas were made both regarding expression of the CALD1 gene and its protein levels. No significant difference was observed in these analyses. The remaining analyses were carried out by grouping the peritoneal and ovarian lesions (see Figs. 1 and 3 ).
CALD1 Expression
Increased CALD1 expression was detected in endometriotic lesions compared with the eutopic endometrium of women with endometriosis and control women in both the proliferative (Fig. 1A) and secretory (Fig. 1B) phases of the menstrual cycle. The phase of the menstrual cycle did not change CALD1 expression in any of the tissues analyzed (data not shown). There was a difference in expression between the eutopic endometrium of women with endometriosis and of controls in the secretory phase (Fig. 1B) of the menstrual cycle.
Caldesmon Protein Levels
The SDS-PAGE profile of the caldesmon protein was clearly different among the eutopic endometrium of both groups and the endometriotic lesion tissue. Two bands with strong intensity were visualized, one of approximately 77 kDa (low molecular weight caldesmon, i.e., l-CaD) and the other of 120 kDa (high molecular weight caldesmon, i.e., h-CaD). The two protein isoforms were strongly detected in the endometriotic lesions but were only weakly detected in the eutopic endometria of the women with endometriosis. In contrast, the lCaD isoform predominated in control endometrium (Fig. 2) .
The phase of the menstrual cycle did not influence the protein levels in any of the tissues analyzed (data not shown). In addition, the caldesmon levels detected in the different tissues showed the same pattern of protein expression in the proliferative and secretory phases of the menstrual cycle. The changes detected are presented in Figure 3 , A-F.
The data for the h-CaD (120 kDa) and l-CaD (77 kDa) isoforms were analyzed separately and then as a whole (caldesmon protein ¼ h-CaD þ l-CaD). A significant increase in caldesmon protein was observed in the endometriotic lesions compared with the eutopic endometrium of women with endometriosis (Fig. 3, A and B) . However, a significantly lower amount of protein was detected in the endometrium of women with endometriosis compared with control endometrium. In addition, there was no significant increase in caldesmon protein in the lesions compared with the controls.
A separate analysis of the caldesmon isoforms also revealed their increased levels in the lesions compared with the paired endometrium (Fig. 3, C-F) , although the difference between the endometria of the patients with endometriosis and the controls was significant only for l-CaD (Fig. 3, E and F) . For hCaD, the protein levels were increased in the lesions compared with the control endometrium and the eutopic endometrium in the same patients (Fig. 3, C and D) .
Immunolocalization of Caldesmon
The caldesmon immunolocalization did not identify differences between the marked cell types in the endometriotic lesions and in the eutopic endometrium. Stromal cells marked positively in the eutopic endometrium from control patients and in the endometriotic lesions (peritoneal and endometrioma) (Fig. 4, A, C, and D) . However, no marked cells were observed in the eutopic endometrium of patients with endometriosis (Fig.  4B ). In addition, no glands were marked in any of the analyzed tissues.
ROC Curves
The diagnostic performance of CALD1 transcripts and of caldesmon protein (h-CaD þ l-CaD) for endometriosis according to disease stage is shown in Table 1 . The gene expression of CALD1 has limited value as a potential diagnostic biomarker for endometriosis. However, the protein
FIG. 1. Relative quantification data for the CALD1 gene by the 2
ÀDDCt method in the analysis of different tissues in the proliferative (A) and secretory (B) phases of the menstrual cycle. Control, endometrium of women without endometriosis; Eutopic, endometrium of women with endometriosis; Lesion, endometriotic lesions (peritoneal and ovarian endometrioma). Comparisons showing significant differences are indicated by the P value in parentheses. The sample number for each group studied is also given. Comparisons between control and eutopic tissues were not paired analyses; comparisons between eutopic tissue and lesions were paired analyses.
CALDESMON IS A POTENTIAL MARKER FOR ENDOMETRIOSIS
encoded by this gene, caldesmon, could be used to discriminate between patients with and without endometriosis with a plausible diagnostic potential both during the proliferative and secretory phases of the menstrual cycle, although it is recommended that this analysis be performed during the proliferative phase because of safety and performance (Fig. 5) .
DISCUSSION
The increased expression of the CALD1 gene in endometriotic lesions has been previously reported in studies of largescale hybridization based on subtractive libraries and microarrays [22] [23] [24] [25] . We used real-time PCR to quantify the expression of this gene to confirm these results. This methodology has been described as the gold standard for the analysis of gene expression because it has high sensitivity, good reproducibility, and a wide quantification range; moreover, this technique reveals potential false-positive results when used for the validation of different screening methodologies [31, 32] . The present results confirm the increased expression of CALD1 in endometriotic peritoneal and ovarian lesions regardless of the phase of the menstrual cycle. In addition, the levels of caldesmon protein were also increased in MEOLA ET AL. endometriotic lesions, but immunolocalization of caldesmon did not identify differences between the marked cell types in the endometriotic lesions and in the eutopic endometrium.
The human caldesmon protein has six isoforms http://www. uniprot.org/uniprot/Q05682). Because of the high content of glutamine residues, the h-CaD and l-CaD isoforms migrate anomalously slowly during SDS-PAGE and have apparent molecular masses of 120-130 kDa and 70-80 kDa, respectively [33, 34] . A differential profile of caldesmon was detected in primary human endometrium stromal cells with induced decidualization. Bands of 77, 95, and 120 kDa were observed by Western blot analyses [35, 36] . In the current study, 77-kDa (l-CaD) and 120-kDa (h-CaD) isoforms were observed in endometrial tissues and endometriotic lesions.
The human CALD1 gene, which encodes the caldesmon (CaD) protein, consists of 14 exons mapped to the 7q33-q34 region [26] . A single gene is encoded by the alternative splicing of exons (exons 3a, 3b, and 4) and distinct promoters (starting with exon 1a-1, 1a-2, 1a-3, or 1b) in the following isoforms: aorta h-CaD (793 amino acid [aa] residues, 93.2 kDa), WI-38 lCaD I (564 aa, 65.7 kDa),WI-38 l-CaD II (538 aa, 62.7 kDa), HeLa l-CaD I (558 aa, 64.3 kDa), and HeLa l-CaD II (532 aa, 61.2 kDa) [26, 37, 38] . This protein has binding sites for actin, myosin, tropomyosin, and Ca 2 -calmodulin [39] . The caldesmon family is composed of two subfamilies: h-CaDs, which are expressed in differentiated smooth muscle cells, and l-CaDs, which are expressed in dedifferentiated smooth muscle cells and in nonmuscle cells [40] . The main N-and C-terminal functional domains of h-CaD and l-CaD are identical, except for the lack of a central region in l-CaD [41] .
The h-CaD and l-CaD isoforms have similar biochemical properties, and when bound to actin, they inhibit actomyosin ATPase activity [42] . The actomyosin system converts the chemical energy of ATP to mechanical force and is the molecular basis for smooth muscle contraction and several events of contraction and motility in nonmuscle cells, such as 
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cytokinesis and phagocytosis [43] . However, this effect can be reversed by Ca 2þ -calmodulin [44] and by phosphorylation, which reduces the affinity of caldesmon for actin [45] . Both hCaD and l-CaD are phosphorylated in vivo, either by smooth muscle stimulation for contraction or by the activation of nonmuscle cells for proliferation or migration [46, 47] . The two isoforms are heat stable; bind to calmodulin, tropomyosin, and actin; inhibit the actomyosin ATPase system (actin-activated Mg 2þ -ATPase myosin activity); and undergo the so-called flipflop and bind to both actin filaments and calmodulin, depending on the concentration of free calcium. Thus, when the Ca 2þ -calmodulin-caldesmon complex is formed, it binds weakly to actin. Regarding intracellular localization, h-CAD is located in the fine filaments (part of the contractility apparatus of smooth muscle cells) and regulates their contractions by inhibiting the actin-myosin interaction, whereas l-CAD is present in actin filaments and stress fibers [40] .
Moreover, l-CaD has alternative functions that include stabilizing the actin filaments of nonmuscle cells to regulate cell contraction, adhesion signaling, and cytoskeleton organization. This isoform also influences granule movement, hormone secretion, and microfilament reorganization during mitosis via specific phosphorylation by cdc2 protein kinase [39] . Several other functions have been directly or indirectly associated with l-CaD, such as the inhibition of cellular contractility and signaling-dependent adhesion [48] and the stabilization of stress fibers, thereby affecting cell morphology, growth, and motility [49] . There is controversy about the regulatory role of this isoform in the formation of podosomes, highly dynamic structures found in mobile and invasive cells, and in cellular invasion [50] and cell migration [51] .
The deregulated expression of CALD1 and its alternative splicings [52, 53] , as well as its loss of function, have been associated with oncogenesis [50] . Zheng et al. [53] have related the differential expression of CALD1 to neovascularization and angiogenesis in gliomas and in tumors of the breast, lung, kidney, stomach, ovary, uterus, and liver. This gene is considered to be a potential serologic marker for gliomas [54] , and its overexpression is related to possible therapeutic functions for glaucoma [55] . Alternative splicing and increased expression of the gene have also been shown in cancer of the colon, bladder and prostate [52] . A study of 60 cell lines derived from human tumors has revealed overexpression of the gene in glioblastomas and renal cell tumors and moderate expression in other sets of tumor lines [56] .
In the present study, higher protein levels of caldesmon were detected in the lesions and in control endometrium compared with the endometrium of women with endometriosis. Eutopic endometrium in patients with endometriosis is an important factor for the understanding of the physiopathology of the disease because this tissue appears to be the center of various alterations [57] . Lower levels of caldesmon in the endometrium of women with endometriosis may increase the motility and invasiveness of this endometrium because if this protein is not binding to actin, then it cannot inhibit the activity of actomyosin ATPase. However, endometriotic lesions are known to have a greater invasive potential than the endometrium [58] . The activity of caldesmon is regulated by phosphorylation [45] and by Ca 2þ -calmodulin [44] , and the expression of the CALM2 gene (which encodes calmodulin) is increased in endometriotic lesions [22] . Thus, regardless of its levels, the function of caldesmon of inhibiting the invasive cellular properties when bound to actin is related to the quantities of Ca 2þþ available in the medium, to phosphorylation, and to the quantity of calmodulin expressed. We speculated that, even if caldesmon is present at the same concentrations in the control endometrium and in endometriotic lesions, the lesions would have a greater invasive potential because of the greater expression of the CALM2 gene, which is found to be increased in the lesions, a fact that would prevent caldesmon from binding to actin and inhibiting cell invasion and motility. Functional studies are needed to clarify the participation of caldesmon in the development of endometriosis.
Several noninvasive tests for endometriosis have been proposed as follows: a combination of CCR1 mRNA, MCP1, and CA-125 measurements showed a sensitivity of 92.2% and a specificity of 81.6% [59] ; IL-6 with a cutoff point of 1.9 pg/ ml showed 71% sensitivity and 66% specificity [60] ; the total amount of ccf nuclear DNA provided 70% sensitivity and 87% specificity [18] ; a serum anti-syntaxin 5 autoantibody showed 53.6% sensitivity and 72.2% accuracy [61] ; a combined analysis of the mRNA levels of MMP-3, MMP-9, VEGF and survivin in the peripheral blood and the serum levels of CA-125 and CA19-9 in women with and without endometriosis showed 87% sensitivity [62] ; serum IL-6 and peritoneal fluid TNF-a showed 90% sensitivity and 67% specificity and 90% specificity and 100% sensitivity, respectively [63] ; the simultaneous evaluation of serum activin A and follistatin concentrations for the diagnosis of ovarian endometrioma showed 41% sensitivity and 90% specificity [64] ; the sensitivity and specificity were 61% and 96% for a serum anti-TMOD3b-autoantibody, 78% and 93% for an antiTMOD3c-autoantibody and 78% and 96% for an antiTMOD3d-autoantibody (used in the detection of the early stages of endometriosis) [13] ; the combined performance of IL-6, IL-8, TNF-a, hsCRP, CA-125, and CA19-9 diagnosed minimal to mild endometriosis with a sensitivity of 94% (specificity of 61%) during the secretory phase and with a sensitivity of 92% (specificity of 63%) during the menstrual phase [15] ; and as a diagnostic marker, urinary vitamin Dbinding protein exhibited 58% sensitivity and 76% specificity [65] .
These body fluid markers have limited success in practice [13, 15, 18, [59] [60] [61] [62] [63] [64] [65] . A double-blind study evaluated the efficacy of an endometrial biopsy to detect nerve fibers (PGP9.5) signifying endometriosis and had a detection sensitivity of 98% (specificity of 83%) [9] . However, a role for PGP9.5-immunoactive nerve fibers in the functional layer of the endometrium has been suggested in pain generation in disorders such as endometriosis, adenomyosis, uterine fibroids, and endometriosis with adenomyosis [66] , which could hinder the clinical use of this feature for the diagnosis of endometriosis. Another group using a combination of PGP9.5, vasoactive intestinal peptide, and substance P was able to predict the presence of minimal to mild endometriosis with 95% sensitivity (100% specificity) [67] . These tests require a careful endometrial biopsy and meticulous attention to immunohistochemistry. Another study used a combined mRNA microarray and proteomic analysis on the same eutopic endometrium sample obtained by biopsy from patients with and without endometriosis, which allowed the diagnosis of endometriosis with 91% sensitivity (80% specificity) [68] .
In the present study, we suggest a possible predictor of endometrial dysregulation in patients with endometriosis that involves a simple methodology. A potential limitation of our study is the fact that others endometrial diseases were not excluded, and therefore prospective studies are needed to confirm the potential of caldesmon as a biomarker exclusively for endometriosis.
